Legal Calls sells exclusive Ozempic NAION leads and signed retainers to law firms. Claimants allege GLP-1 drugs such as Ozempic, Wegovy and Mounjaro caused NAION, a sudden optic-nerve injury that can cause permanent vision loss. Leads come from our own Meta, TikTok and Google ads and are delivered by CRM, API, email or warm transfer.
| Case type | Pharmaceutical product liability (GLP-1 receptor agonists) |
| Litigation | MDL No. 3163, E.D. Pa., Judge Karen Spencer Marston (created Dec 15, 2025) |
| Alleged injuries | NAION (optic nerve “eye stroke”) with sudden, often permanent vision loss |
| Lead sources | Meta, TikTok & Google ads — no affiliates |
| What you get | Exclusive leads or signed retainers |
| Delivery | CRM, API, email or warm transfer |
| Intake | In-house team, under 1-minute speed-to-lead |
| Proof | TrustedForm certificate, call recordings, ad account access |
| Volume | On request |
| Last reviewed | November 2026 |
On December 15, 2025 the JPML centralized GLP-1 vision-loss claims in MDL No. 3163, In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation. It sits in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. Defendants are Novo Nordisk and Eli Lilly.
GLP-1 gastroparesis and other GI claims are a separate track in MDL 3094, though the same judge handles both. New Jersey also has a state-court multicounty litigation for GLP-1 NAION cases in Bergen County, before Judge Gregg A. Padovano.
A July 2, 2026 case management order directed early discovery and motions on general causation and preemption/warning adequacy. As of November 2026 the MDL is in pretrial discovery, with more than 200 actions pending in fall 2026 per JPML reports. No bellwether trial dates or settlement had been announced.
On November 9, 2026 the FDA required all GLP-1 drug labels to add a warning about a potential increased risk of NAION to Warnings and Precautions. The FDA did not find that the drugs cause NAION. The timing of this warning bears on the failure-to-warn theory, especially for vision loss before it.
Sources: Separate Litigation Created for NAION Injuries Caused by GLP-1 Drugs (Pope McGlamry) · MDL 3163 Case Management Order No. 12, July 2, 2026 · FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (Pharmacy Times) · New Jersey GLP-1 NAION Multicounty Litigation leadership (Anapol Weiss). Status as of November 2026.
Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.
Exclusive Ozempic NAION leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.
Signed Ozempic NAION retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.
Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.
Yes. NAION claims are centralized in MDL No. 3163 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston, created on December 15, 2025. It is separate from the GLP-1 gastrointestinal MDL 3094.
The core injury is non-arteritic anterior ischemic optic neuropathy (NAION), usually sudden and painless vision loss in one or both eyes. Intake focuses on an eye-specialist NAION diagnosis made after GLP-1 use began.
The MDL involves Novo Nordisk drugs (Ozempic, Wegovy, Rybelsus, Saxenda) and Eli Lilly drugs (Mounjaro, Zepbound, Trulicity).
It is being added. On November 9, 2026 the FDA required all GLP-1 labels to warn of a potential increased risk of NAION. The FDA did not conclude the drugs cause NAION.
Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.
Yes. Firms can buy exclusive leads or signed retainers, priced as a percentage of ad spend or a fixed price per signed retainer.
Ozempic Gastroparesis Leads · Ozempic Leads · Depo-Provera Leads · Mass Tort Intake · All mass tort case leads
Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.
Book a time with our VP, and he’ll walk you through pricing and strategy step by step.